🇺🇸 JUST IN: T. Rowe Price files for actively managed crypto ETF. https://t.co/OdCYnFS4ag ...

🚨 BREAKING: T. Rowe Price has officially filed with the SEC to launch the T. Rowe Price Active Crypto ETF. https://t.co/O3yI35b9A3 ...

Core Viewpoint - T. Rowe Price has filed for an actively managed crypto exchange-traded fund, indicating a significant move into the cryptocurrency investment space [1] Group 1 - The filing represents T. Rowe Price's strategic expansion into the cryptocurrency market [1] - The actively managed approach suggests a focus on dynamic investment strategies within the crypto sector [1]

Active ETF Channelchuck jaffeetf of the weekexpert insightsPodcastsT. Rowe PriceTAGGtodd rosenbluth Earn free CE credits and discover new strategies Load More For more news, information, and strategy, visit the Active ETF Content Hub. RELATED TOPICS VettaFi's Head of Research Todd Rosenbluth discussed the T. Rowe Price QM US Bond ETF (TAGG)on this week's "ETF of the Week†podcast with Chuck Jaffe of "Money Life.†...

Group 1 - The core finding of Vanguard's annual survey indicates that 58% of Americans are not on track for a comfortable retirement [1] - A specific example is provided of a 35-year-old millennial, Janet, who earns the median income of $62,000 but only has $15,000 saved for retirement, suggesting she is behind on savings [1][2] - T. Rowe Price recommends that by age 35, individuals should have saved 1 to 1.5 times their salary, which in Janet's case would be between $62,000 and $93,000 [2] Group 2 - The article emphasizes the importance of aggressive saving for young individuals like Janet to secure their retirement [3] - Steps to set retirement savings goals include determining the desired retirement age, estimating future salary growth, and calculating the necessary nest egg, which should ideally be 10 times the final salary by age 67 [4][5] - It is suggested that individuals use online savings calculators to assess how much they need to save monthly to meet their retirement goals [5]

Core Insights - OHA has increased its investment in IDEAL Holdings' Corporate Vehicle to 25% with an additional €41 million, enhancing the company's cash position [1][2] - The Corporate Vehicle holds most of IDEAL Holdings' investments, including attica Department Stores and various ICT companies [2] - OHA retains the right to co-invest up to an additional €200 million over the next two years, supporting IDEAL Holdings' growth and strategic expansion [3] Company Overview - IDEAL Holdings is a listed holding company with a diversified investment portfolio, focusing on companies with sustainable growth prospects [4] - Key investments include BYTE S.A., ADACOM S.A., BLUESTREAM SOLUTIONS S.A., attica Department Stores S.A., Barba Stathis S.A., and Chalvatzis Makedoniki S.A. [4] OHA Overview - Oak Hill Advisors (OHA) is a global credit-focused alternative asset manager with approximately $98 billion in assets under management as of June 30, 2025 [5] - OHA emphasizes long-term partnerships and provides customized credit solutions across market cycles [5]

Core Insights - T. Rowe Price Group reported preliminary assets under management (AUM) of $1.77 trillion as of September-end, an increase from $1.73 trillion at the end of August [3] Summary by Asset Class - Equity AUM stood at $885 billion [3] - Fixed income, including money market, accounted for $208 billion [3] - Multi-asset AUM was reported at $618 billion [3] - Alternatives AUM totaled $56 billion [3]

Core Insights - T. Rowe Price Group, Inc. reported preliminary assets under management of $1.77 trillion as of September 30, 2025, with net outflows of $2.0 billion for September and $7.9 billion for the quarter [1][5]. Assets Under Management - As of September 30, 2025, the breakdown of assets under management includes: - Equity: $867 billion, down from $830 billion in August 2025 [3] - Fixed Income: $208 billion, up from $205 billion in August 2025 [3] - Multi-Asset: $618 billion, up from $602 billion in August 2025 [3] - Alternatives: $56 billion, up from $55 billion in August 2025 [3] - Target Date Retirement Portfolios: $538 billion, up from $520 billion in August 2025 [3] Upcoming Earnings Release - T. Rowe Price is scheduled to release its Q3 2025 earnings on October 31, 2025, at 7:00 AM ET, followed by an earnings call from 8:00 to 8:45 AM ET [4].

Core Viewpoint - T. Rowe Price (TROW) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, continuing a trend of positive earnings surprises [1]. Earnings Performance - T. Rowe Price has consistently beaten earnings estimates, with an average surprise of 5.44% over the last two quarters [2]. - In the last reported quarter, T. Rowe achieved earnings of $2.24 per share, exceeding the Zacks Consensus Estimate of $2.15 per share, resulting in a surprise of 4.19% [3]. - For the previous quarter, the company reported earnings of $2.23 per share against an expected $2.09 per share, delivering a surprise of 6.70% [3]. Earnings Estimates and Predictions - Earnings estimates for T. Rowe Price have been trending higher, supported by its history of earnings surprises [6]. - The stock has a positive Zacks Earnings ESP of +5.12%, indicating increased analyst optimism regarding its near-term earnings potential [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat [9]. Earnings ESP Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].

Group 1 - MapLight Therapeutics, a biotechnology company based in Redwood City, California, plans to raise approximately $251 million through an IPO by issuing 14.8 million shares at a price of $17 per share, resulting in a fully diluted market capitalization of about $820 million [1] - The company focuses on developing innovative therapies for neuropsychiatric and central nervous system (CNS) diseases, with its main candidate drug ML-007C-MA aimed at treating schizophrenia and Alzheimer's disease psychosis (ADP) [2][3] - T. Rowe Price has committed to purchasing approximately $40 million worth of shares, representing 16% of the total offering, and MapLight plans to conduct an additional $8 million private placement with Goldman Sachs [1] Group 2 - Due to the current U.S. government shutdown, the SEC has paused the formal review of registration statements, prompting MapLight to utilize a rare provision under the Securities Act of 1933 to advance its listing process [2] - The company intends to price its shares 20 days after filing, but may reassess its strategy if the SEC resumes normal operations before October 26 [2] - MapLight was founded in 2018 and plans to list on NASDAQ under the ticker "MPLT," with Morgan Stanley, Jefferies, Leerink Partners, and Stifel serving as joint underwriters for the offering [3]